Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Cited by (1,021)

Items 801–900 of 1,021

1. Renal effects of immune checkpoint inhibitors
   Hassan Izzedine, Christine Mateus, C. Boutros, Caroline Robert, Philippe Rouvier, Zahir Amoura, Alexis Mathian · 2016 · Nephrology Dialysis Transplantation
2. Immune checkpoint inhibitors in renal cell carcinoma
   Kirsty Ross, Robert J. Jones · 2017 · Clinical Science
3. Immune Checkpoint Blockade
   Jarushka Naidoo, David B. Page, Jedd D. Wolchok · 2014 · Hematology/Oncology Clinics of North America
4. Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma
   Patrick Alexander Ott, Omid Hamid, Anna C. Pavlick, Harriet M. Kluger, Kevin B. Kim, Peter D. Boasberg, Ronit Simantov, Elizabeth M. Crowley, Jennifer A. Green, Thomas R. Hawthorne et al. · 2014 · Journal of Clinical Oncology
5. Targeting MAPK pathway in melanoma therapy
   Yabin Cheng, Guohong Zhang, Gang Li · 2013 · Cancer and Metastasis Reviews
6. Targeting Costimulatory Molecules to Improve Antitumor Immunity
   Daria Capece, Daniela Verzella, Mariafausta Fischietti, Francesca Zazzeroni, Edoardo Alesse · 2012 · BioMed Research International
7. Combination Strategies to Enhance Antitumor ADCC
   Holbrook E K Kohrt, Roch Houot, Aurélien Marabelle, Hearn Jay Cho, Keren Osman, Matthew Jordan Goldstein, Ronald Levy, Joshua Brody · 2012 · Immunotherapy
8. Health-related quality of life results from the phase III CheckMate 067 study
   Dirk Schadendorf, James Larkin, Jedd D. Wolchok, Frank Stephen Hodi, Vanna Chiarion‐Sileni, Rene C. Gonzalez, Piotr Lukasz Rutkowski, Jean‐Jacques Grob, Charles Lance Cowey, Christopher D. Lao et al. · 2017 · European Journal of Cancer
9. Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin
   Jain, Varun, Mohebtash, Mahsa, Rodrigo, Maria E., Ruiz, George, Atkins, Michael B., Barac, Ana · 2018 · Journal of Immunotherapy
10. Aging, immune senescence, and immunotherapy: a comprehensive review
    Elias, Rawad, Hartshorn, Kevan, Rahma, Osama, Lin, Nina, Snyder-Cappione, Jennifer E. · 2018 · Seminars in Oncology
11. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab
    Or Cohen‐Inbar, Han-Hsun Shih, Zhiyuan Xu, David J. Schlesinger, Jason P. Sheehan · 2017 · Journal of neurosurgery
12. Immunotherapy of cancers comes of age
    Hila Yousefi, Jianda D. Yuan, Mahsa Keshavarz‐Fathi, Joseph F. Murphy, Nima Rezaei · 2017 · Expert Review of Clinical Immunology
13. Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives
    Elisa A. Rozeman, Tim J. A. Dekker, John B.A.G. Haanen, Christian U. Blank · 2017 · American Journal of Clinical Dermatology
14. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer
    Yoshie Kobayashi, Seung‐Oe Lim, Hirohito Yamaguchi · 2019 · Seminars in Cancer Biology
15. Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial
    Hans‐Joachim Schmoll, Burghardt Wittig, Dirk Arnold, Jorge Riera‐Knorrenschild, Dieter Nitsche, Hendrik Kroening, Frank Mayer, Johannes Andel, Reinhard Ziebermayr, Werner Scheithauer · 2014 · Journal of Cancer Research and Clinical Oncology
16. Prognostic Value of BRAF V600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes
    Stéphanie Moreau, Philippe Saïag, Philippe Aegerter, D. Bosset, Christine Longvert, Zofia Hélias‐Rodzewicz, Cristi Marin, Frédérique Peschaud, S Chagnon, Utte Zimmermann et al. · 2012 · Annals of Surgical Oncology
17. Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies
    Caroline Robert, Jean‐Charles Soria, Alexander M.M. Eggermont · 2013 · European Journal of Cancer
18. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis
    Tengfei Zhang, Jing Xie, Seiji Arai, Liping Wang, Xuezhong Shi, Ni Shi, Fen Ma, Sen Chen, Lan Ji Huang, Li Yang et al. · 2016 · Oncotarget
19. Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience
    Raphael J. Louie, Matthew C Perez, Mohammad Raheel Jajja, James X. Sun, Frances A. Collichio, Keith A. Delman, Michael Lowe, Amod A. Sarnaik, Jonathan S. Zager, David W. Ollila · 2019 · Journal of the American College of Surgeons
20. Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance
    Terry R. Medler, Tiziana Cotechini, Lisa M. Coussens · 2015 · Trends in cancer
21. Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review
    Jonathan Daniel Schoenfeld, Anand Mahadevan, Scott Floyd, Michael A. Dyer, Paul J. Catalano, Brian Michael Alexander, David F. McDermott, I.D. Kaplan · 2015 · Journal for ImmunoTherapy of Cancer
22. Targeted Therapy for Melanoma
    Deborah J. L. Wong, Antoni Ribas · 2015 · Cancer treatment and research
23. Approaches to modernize the combination drug development paradigm
    Daphne Day, Lillian L. Siu · 2016 · Genome Medicine
24. The application of nanotechnology in immune checkpoint blockade for cancer treatment
    Huan Deng, Zhiping Zhang · 2018 · Journal of Controlled Release
25. The Role of Immune Checkpoint Inhibitors in Cancer Therapy
    Ahmed Basudan · 2022 · Clinics and Practice
26. Vemurafenib Sensitivity Skin Reaction after Ipilimumab
    James J. Harding, Melissa P. Pulitzer, Paul B. Chapman · 2012 · New England Journal of Medicine
27. Inflammation in uveal melanoma
    Inge H. G. Bronkhorst, Martine Johanna Jager · 2012 · Eye
28. Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
    Anna Śledzińska, Laurie Menger, Katharina F. Bergerhoff, Karl S. Peggs, Sergio A. Quezada · 2015 · Molecular Oncology
29. Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies
    S. Jang, Michael B. Atkins · 2013 · Clinical Pharmacology & Therapeutics
30. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers
    Arun Rajan, Chul Kim, Christopher Ryan Heery, Udayan Guha, James L. Gulley · 2016 · Human Vaccines & Immunotherapeutics
31. Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy
    Kimiteru Ito, Heiko M. Schöder, Rebecca Siew Yan Teng, John Laurence Humm, Ai Ni, Jedd D. Wolchok, Wolfgang Weber · 2018 · European Journal of Nuclear Medicine and Molecular Imaging
32. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies
    Joseph J. Jennings, Rohan H. Mandaliya, Ahmad Nakshabandi, James H. Lewis · 2019 · Expert Opinion on Drug Metabolism & Toxicology
33. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
    Nicholas D. Klemen, Melinda Wang, Jill Carol Rubinstein, Kelly L. Olino, James E. Clune, Stephan Ariyan, Charles H. Cha, Sarah Ann Weiss, Harriet M. Kluger, Mario Sznol · 2020 · Journal for ImmunoTherapy of Cancer
34. Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
    Nethanel Asher, Guy Ben‐Betzalel, Shaked Lev Ari, Ronnie Shapira‐Frommer, Yael Steinberg‐Silman, Neta Gochman, Jacob Schachter, Tomer Meirson, Gal Markel · 2020 · Cancers
35. Multi-kingdom gut microbiota analyses define bacterial-fungal interplay and microbial markers of pan-cancer immunotherapy across cohorts
    Xiaowen Huang, Muni Hu, Tiantian Sun, Jiantao Li, Yilu Zhou, Yuqing Yan, Baoqin Xuan, Jilin Wang, Hua Xiong, Linhua Ji et al. · 2023 · Cell Host & Microbe
36. Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)
    Jun Guo, Shukui Qin, Jun Liang, Tongyu Lin, Lu Si, Xiaohong Chen, Zhihong Chi, Chuanliang Cui, Nan Du, Yun Fan et al. · 2016 · Chinese Clinical Oncology
37. The impact of the intestinal microbiota in therapeutic responses against cancer
    Anne‐Gaëlle Goubet, Romain Daillère, Bertrand Routy, Lisa Derosa, Paula M. Roberti, Laurence Zitvogel · 2018 · Comptes Rendus Biologies
38. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer
    Alemohammad, Hajar, Najafzadeh, Basira, Asadzadeh, Zahra, Baghbanzadeh, Amir, Ghorbaninezhad, Farid, Najafzadeh, Arezoo, Safarpour, Hossein, Bernardini, Renato, Brunetti, Oronzo, Sonnessa, Margherita et al. · 2022 · Biomedicine & Pharmacotherapy
39. The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy
    Joanne Leung, Woong‐Kyung Suh · 2014 · Immune Network
40. Time to dissect the autoimmune etiology of cancer antibody immunotherapy
    Michael Lawrence Dougan, Massimo Pietropaolo · 2020 · Journal of Clinical Investigation
41. Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma
    Mark Ross Middleton, Philip Adam Friedlander, Omid Hamid, ADIL I. DAUD, Ruth Plummer, Nancy Falotico, Brenda Chyla, Fang Jiang, Evelyn Mary McKeegan, Nael Mohamed Mostafa et al. · 2015 · Annals of Oncology
42. Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance
    Antonia L. Pritchard, Nicholas K. Hayward · 2013 · Clinical Cancer Research
43. Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives
    Michael B. Atkins, James Larkin · 2016 · JNCI Journal of the National Cancer Institute
44. Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
    Noboru Yamamoto, Hiroshi Nokihara, Yasuhide Yamada, Takashi Shibata, Yosuke Tamura, Yoshitaka Seki, Kazunori Honda, Yuko Tanabe, Hiroshi Wakui, Tomohide Tamura · 2016 · Investigational New Drugs
45. The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
    Jodi A. McKenzie, Rina M. Mbofung, Shruti Malu, Min Zhang, Emily L. Ashkin, Seram Devi, Leila J. Williams, Trang N. Tieu, Weiyi Peng, Sunila Pradeep et al. · 2017 · JNCI Journal of the National Cancer Institute
46. Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
    Lídia Robert, Christina L. Harview, Ryan Emerson, Xiaoyan Wang, Stephen Mok, Blanca Homet, Begonya Comin-Anduix, Richard Chikara Koya, Harlan S. Robins, Paul C. Tumeh et al. · 2014 · OncoImmunology
47. VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma
    Xinqi Wu, Anita Giobbie‐Hurder, Xiaoyun Liao, Donald P. Lawrence, David F. McDermott, Jun Min Zhou, Scott J. Rodig, Frank Stephen Hodi · 2016 · Cancer Immunology Research
48. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
    Teresa M. Petrella, Caroline Robert, Erika Richtig, Wilson H. Miller, Giuseppe Valentino Masucci, Euan Thomas Walpole, Célèste Lebbé, Neil Matthew Steven, Mark Ross Middleton, Darcy A. Hille et al. · 2017 · European Journal of Cancer
49. Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer
    Mark Lawler, Deborah Alsina, Richard Adams, Annie S. Anderson, Gina M. Brown, Nicola S. Fearnhead, Stephen William Fenwick, Stephen P Halloran, Daniel Hochhauser, Mark A. Hull et al. · 2017 · Gut
50. Macrophage-Mediated Subversion of Anti-Tumour Immunity
    Valeria Quaranta, Michael C. Schmid · 2019 · Cells
51. Trials and tribulations of pancreatic cancer immunotherapy
    Daniel R. Principe, Murray Korc, Suneel Deepak Kamath, Hidayatullah G. Munshi, Ajay Rana · 2021 · Cancer Letters
52. Therapeutic Antibodies Against Cancer
    Mark J. Adler, Dimiter Stanchev Dimitrov · 2012 · Hematology/Oncology Clinics of North America
53. Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study
    On behalf of the Italian Melanoma Intergroup (IMI), Maria Pia Pistillo, Vincenzo Fontana, Anna Morabito, Béatrice Dozin, Stefania Laurent, Roberta Carosio, Barbara Banelli, Francesca Ferrero, Laura Spano et al. · 2018 · Cancer Immunology Immunotherapy
54. Translational research in oncology—10 years of progress and future prospects
    James H. Doroshow, Shivaani Kummar · 2014 · Nature Reviews Clinical Oncology
55. Current and Future Roles of Targeted Therapy and Immunotherapy in Advanced Melanoma
    Anthony J. Olszanski · 2014 · Journal of Managed Care Pharmacy
56. Gene-expression profiling to predict responsiveness to immunotherapy
    Nigel Balfour Jamieson, Ajay V. Maker · 2016 · Cancer Gene Therapy
57. HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation
    Josefa Antonia Rodrı́guez · 2017 · Oncology Letters
58. Aging, Cancer and Immunity
    Hong Hong, Qi Wang, Jing Li, Hans B. Liu, Xin Meng, Haiyan Zhang · 2019 · Journal of Cancer
59. Immune checkpoint inhibitors‐induced neuromuscular toxicity: From pathogenesis to treatment
    Dimitri Psimaras, Roser Velasco, Cristina Birzu, Stefano Tamburin, Maryam B. Lustberg, Jordi Bruna, Andreas A. Argyriou · 2019 · Journal of the Peripheral Nervous System
60. Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens
    Harm Westdorp, Annette E. Sköld, Berit A. Snijer, Sebastian Franik, Sasja F. Mulder, Pierre P Major, Ronan Foley, Winald R. Gerritsen, I. Jolanda M. de Vries · 2014 · Frontiers in Immunology
61. The scope of nanoparticle therapies for future metastatic melanoma treatment
    Francesca Baldelli Bombelli, Carl A Webster, Marc D. Moncrieff, Victoria Sherwood · 2014 · The Lancet Oncology
62. Association Between Circulating Tumor Cells and Prognosis in Patients With Stage III Melanoma With Sentinel Lymph Node Metastasis in a Phase III International Multicenter Trial
    Sojun Hoshimoto, Tatsushi Shingai, Donald L. Morton, Christine T. Kuo, Mark B. Faries, Kelly K. Chong, David A. Elashoff, He-Jing Wang, Robert M. Elashoff, Dave S.�B. Hoon · 2012 · Journal of Clinical Oncology
63. Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy
    Kelly Kersten, Camilla Salvagno, Karin E. de Visser · 2015 · Frontiers in Immunology
64. Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer
    Naveen K.R. Chalakur-Ramireddy, Suresh B. Pakala · 2018 · Bioscience Reports
65. A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T-lymphocyte tumor cell killing
    Lizotte, Patrick H., Hong, Ruey-Long, Luster, Troy A., Cavanaugh, Megan E., Taus, Luke J., Wang, Stephen, Dhaneshwar, Abha, Mayman, Naomi, Yang, Aaron, Kulkarni, Meghana et al. · 2018 · Cancer Immunology Research
66. Ipilimumab in patients with melanoma and autoimmune disease
    Chrisann Kyi, Richard D. Carvajal, Jedd D. Wolchok, Michael A. Postow · 2014 · Journal for ImmunoTherapy of Cancer
67. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
    Kaamar Azijli, Ellen Stelloo, Godefridus J. Peters, Alfons J.M. van den Eertwegh · 2014 · PubMed
68. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies
    Kimberly Mayumi Komatsubara, Richard D. Carvajal · 2017 · Current Oncology Reports
69. Cardiotoxicity of Immune Checkpoint Inhibitors
    Lili Zhang, Maeve Jones‐O’Connor, Magid Awadalla, Daniel A. Zlotoff, Paaladinesh Thavendiranathan, John D. Groarke, Alexandra–Chloé Villani, Alexander Richard Lyon, Tomas G. Neilan · 2019 · Current Treatment Options in Cardiovascular Medicine
70. Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a/Kruppel-like factor 4 signaling
    Wenzheng Xia, Changlin Zou, Hanbin Chen, Congying Xie, Meng Hou · 2020 · Cell Death and Disease
71. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
    Antoni Ribas, Alain Patrick Algazi, Paolo A. Ascierto, Marcus Otho Butler, Sunandana Chandra, Michael S. Gordon, Leonel Fernando Hernandez-Aya, Donald P. Lawrence, Jose Lutzky, Wilson H. Miller et al. · 2020 · Nature Communications
72. New-Onset Mediastinal and Central Nervous System Sarcoidosis in a Patient with Metastatic Melanoma Undergoing CTLA4 Monoclonal Antibody Treatment
    Kevin P. Murphy, Marcus Peter Kennedy, Josephine E. Barry, Kevin N. O'Regan, Derek Gerard Power · 2014 · Oncology Research and Treatment
73. Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth
    Alice Hervieu, Cédric Rébé, Frédérique Végran, Fanny Chalmin, Mélanie Bruchard, Pierre Vabres, Lionel Apétoh, François Ghiringhelli, Grégoire Mignot · 2012 · Journal of Investigative Dermatology
74. Characterization of the inflammatory response to solid cancer metastases in the human brain
    Anna Sophie Berghoff, Hans Lassmann, Matthias Preusser, Romana Höftberger · 2012 · Clinical & Experimental Metastasis
75. The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action
    Laurie Hamtiaux, Julien Masquelier, Giulio G. Muccioli, Caroline Bouzin, Olivier Féron, Bernard Gallez, Didier M. Lambert · 2012 · BMC Cancer
76. Triple-negative breast cancer: are we making headway at least?
    Mónica Arnedos, Céline Bihan, Suzette Delaloge, Fabrice André · 2012 · Therapeutic Advances in Medical Oncology
77. Melanoma immunotherapy
    Martina Sanlorenzo, Igor Vujic, Christian Posch, Akshay Dajee, Adam Yen, Sarasa T. Kim, Michelle T. Ashworth, Michael D. Rosenblum, Alain Patrick Algazi, Simona Osella‐Abate et al. · 2014 · Cancer Biology & Therapy
78. Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis
    Fausto Petrelli, Raffaele Ardito, Barbara Merelli, Veronica Lonati, Mary Cabiddu, Silvia Seghezzi, Sandro Barni, Antonio Ghidini · 2018 · Melanoma Research
79. Immune checkpoint inhibitors for cancer and venous thromboembolic events
    Jingyi Gong, Zsófia D. Drobni, Raza M. Alvi, Sean Murphy, Ryan Joseph Sullivan, Sarah E. Hartmann, Hannah K. Gilman, H Lee, Leyre Zubiri, Vineet K. Raghu et al. · 2021 · European Journal of Cancer
80. Targeting T Cell Immunometabolism for Cancer Immunotherapy; Understanding the Impact of the Tumor Microenvironment
    Mary B. Mockler, Melissa Jane Conroy, Joanne Lysaght · 2014 · Frontiers in Oncology
81. Chemotherapy in Esophageal Cancer
    David Paul Kelsen · 2023 · Frontiers research topics
82. Vemurafenib in Patients With BRAF V600E Mutation–Positive Advanced Melanoma
    Marcus C. Ravnan, Mazen S. Matalka · 2012 · Clinical Therapeutics
83. Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
    Maria Jure‐Kunkel, Gregg R. Masters, Emel Girit, Gennaro Dito, Francis Y. Lee, John T. Hunt, Rachel W. Humphrey · 2013 · Cancer Immunology Immunotherapy
84. PD-1 Expression on Mycobacterium tuberculosis-Specific CD4 T Cells Is Associated With Bacterial Load in Human Tuberculosis
    Cheryl L. Day, Deborah Ann Abrahams, Rubina Bunjun, Lynnett Stone, Marwou de Kock, Gerhard Walzl, Robert John Wilkinson, Wendy A. Burgers, Willem Albert Hanekom · 2018 · Frontiers in Immunology
85. JAVELIN Head and Neck 100: A Phase III Trial of Avelumab and Chemoradiation for Locally Advanced Head and Neck Cancer
    Yao Yu, Nancy Y. Lee · 2018 · Future Oncology
86. Liver biopsy findings in patients on immune checkpoint inhibitors
    Justine Vanessa Cohen, Michael Lawrence Dougan, Leyre Zubiri, Kerry Lynn Reynolds, Ryan Joseph Sullivan, Joseph Misdraji · 2020 · Modern Pathology
87. Risk of Gastrointestinal Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis
    Omar Mohammed Abdel-Rahman, Hesham M. Elhalawani, Mona Fouad · 2015 · Immunotherapy
88. Immunotherapy in lung cancer.
    Erminia Massarelli, Vassiliki A. Papadimitrakopoulou, James William Welsh, Chad Z. Tang, Anne S. Tsao · 2014 · Europe PMC (PubMed Central)
89. Lung cancer: potential targets for immunotherapy
    Éric Tartour, Laurence Zitvogel · 2013 · The Lancet Respiratory Medicine
90. Immune-priming of the Tumor Microenvironment by Radiotherapy
    Vafa Shahabi, Michael A. Postow, David P. Tuck, Jedd D. Wolchok · 2013 · American Journal of Clinical Oncology
91. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer
    Jennifer McLachlan, Stergios Boussios, Alicia F. C. Okines, Daria Glaessgen, S. Bodlar, Ria Kalaitzaki, A. Taylor, Susan Lalondrelle, Martin Eric Gore, Stan B. Kaye et al. · 2016 · Clinical Oncology
92. Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies
    Nausicaa Clemente, Benedetta Ferrara, Casimiro Luca Gigliotti, Elena Maria Boggio, Maria Teresa Capucchio, Elena Biasibetti, Davide Schiffer, Marta Mellai, Laura Annovazzi, Luigi Cangemi et al. · 2018 · International Journal of Molecular Sciences
93. Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
    Yu Jing Yuan, Abdalla Adam, Chen Zhao, Honglei Chen · 2021 · Cancers
94. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
    the Cancer and Leukemia Group B, Thomas Frank Gajewski, April K.S. Salama, Donna Niedzwiecki, Jeffrey E. Johnson, Gerald P. Linette, Cynthia J. Bucher, Michelle A. Blaskovich, Saı̈d M. Sebti, Frank G. Haluska · 2012 · Journal of Translational Medicine
95. Abdominoperineal Resection Provides Better Local Control But Equivalent Overall Survival to Local Excision of Anorectal Malignant Melanoma
    Akihisa Matsuda, Masao Miyashita, Satoshi Matsumoto, Goro Takahashi, Takeshi Matsutani, Takeshi Yamada, Taro Kishi, Eiji Uchida · 2014 · Annals of Surgery
96. Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis
    Katharina Lankes, Gheorghe Hundorfean, Thomas Harrer, Ansgar J. Pommer, Abbas Agaimy, Irena Angelovska, Azadeh Tajmir-Riahi, J. Göhl, Gerold Schuler, Markus Friedrich Neurath et al. · 2016 · OncoImmunology
97. Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
    Vishwajith Sridharan, Danielle Nina Margalit, Stephanie A Lynch, Mariano Severgnini, Jun Min Zhou, Nicole Grace Chau, Guilherme Rabinowits, Jochen H. Lorch, Peter S. Hammerman, Frank Stephen Hodi et al. · 2016 · British Journal of Cancer
98. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Vulvovaginal Melanomas
    Mario M. Leitão, Xi Cheng, Anne L. Hamilton, Nadeem Ahmad Siddiqui, Ina Maria Jurgenliemk-Schulz, Sven Mahner, Elisabeth H. Åvall-Lundqvist, Kidong Kim, Gilles Freyer · 2014 · International Journal of Gynecological Cancer
99. Therapeutic Advances and Treatment Options in Metastatic Melanoma
    Douglas Buckner Johnson, Jeffrey Alan Sosman · 2015 · JAMA Oncology
100. Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1
     Ester Simeone, Paolo A. Ascierto · 2012 · Journal of Immunotoxicology